Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer

Avastin unraveled by stratification study, Roche seeks validation

This article was originally published in Scrip

Executive Summary

  • Reanalysis of Avastin registration trial brings Roche strategy for making universal Avastin use in oncology into question again.
  • Study suggests less than half of Avastin treated colorectal cancer patients benefit from the drug.
  • Similar stratification may be demonstrated in other Avastin indication.
  • UK’s National Health Service could benefit financially from running confirmatory study.
  • Since Avastin is approved and reimbursed in colorectal cancer in many market, the UK where reimbursement is not automatic is one of the few markets where such a trial could be performed ethically.

    • Table

    View full table

    Topics

    Tags:
    Cancer
    Latest Headlines

    Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

    Humira Market Erosion Is Continuing As Expected, AbbVie Says

    Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

    Analysis: Novo And Lilly Make Their Money Work

    See All
    UsernamePublicRestriction

    Register

    SC019230

    Ask The Analyst

    Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

    Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts

    Cancel

    This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

    Printed By